GlassScriptPhysician profile
Shaher Altoumah
NPI 1962976712
$2,537.01
in general payments reported to CMS, 2019-2025
20 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $300 · 2023: $86.31 · 2024: $762 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $583.05 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $310.08 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $296.24 | 2024-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $213.96 | 2022-2025 | |
| Genzyme Corporation | $194.64 | 2024-2025 | |
| Exact Sciences Corporation | $147.12 | 2025 | The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $116.58 | 2024 | Nexlizet, Nexletol |
| Glaxosmithkline, LLC. | $116.45 | 2022-2024 | Trelegy Ellipta |
| Shield Therapeutics INC | $92.72 | 2023-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.68 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $68.93 | 2022-2025 | |
| Lilly USA, LLC | $47.28 | 2023-2025 | Mounjaro, Jardiance |
| Biohaven Pharmaceuticals, INC. | $47.08 | 2021 | |
| Sunovion Pharmaceuticals INC. | $43.26 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.15 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.71 | 2021-2025 | Capvaxive, M-M-R II, Gardasil 9 |
| Urovant Sciences INC | $33.19 | 2022 | |
| Edwards Lifesciences Corporation | $23.05 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Phathom Pharmaceuticals, INC. | $22.40 | 2024 | Voquezna |
| Abbvie INC. | $18.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaher Altoumah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.